Aside from mutation‐specific vulnerabilities within BAF complexes themselves, cancers with mutations in the most frequently affected BAF subunits ARID1A, SMARCA4/2, and SMARCB1255 have several other synthetic lethal interactions that can be leveraged therapeutically. This evidence concerns the gene SMARCA4 and cancer.